Vitamin D Analog Shows Potential in Enhancing Pancreatic Cancer Treatment
A clinical trial led by Dana-Farber Cancer Institute researchers has explored the use of paricalcitol, a vitamin D analog, in combination with standard chemotherapy for treating metastatic pancreatic cancer. The study, published in Nature Cancer, found that paricalcitol helps reshape the tumor microenvironment, making the cancer more susceptible to treatment. Patients receiving paricalcitol showed improved chemotherapy responses and increased progression-free survival. The trial also noted that patients with high vitamin D receptor expression had the longest overall survival. This approach leverages the body's natural systems to reduce fibrotic and inflammatory responses, potentially overcoming therapeutic resistance in pancreatic cancer. 
